TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has been given a consensus recommendation of "Buy" by the ten research firms that are currently covering the stock, Marketbeat reports. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $11.56.

Several equities analysts recently issued reports on TLSI shares. Lake Street Capital began coverage on TriSalus Life Sciences in a research report on Thursday, February 13th. They issued a "buy" rating and a $10.00 target price on the stock. Canaccord Genuity Group restated a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Finally, Roth Mkm reiterated a "buy" rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th.

Insiders Place Their Bets

In other news, CEO Mary T. Szela acquired 4,826 shares of the business's stock in a transaction that occurred on Monday, January 27th. The shares were purchased at an average price of $5.42 per share, for a total transaction of $26,156.92. Following the acquisition, the chief executive officer now owns 429,503 shares of the company's stock, valued at $2,327,906.26. This represents a 1.14 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Emmett Young acquired 24,000 shares of the company's stock in a transaction that occurred on Monday, January 27th. The stock was acquired at an average price of $5.40 per share, with a total value of $129,600.00. Following the acquisition, the chief financial officer now directly owns 24,000 shares of the company's stock, valued at approximately $129,600. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 54,856 shares of company stock worth $294,608. Company insiders own 32.80% of the company's stock.

Institutional Investors Weigh In On TriSalus Life Sciences

Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in shares of TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company's stock valued at $924,000 after purchasing an additional 62,542 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $92,000. Renaissance Technologies LLC purchased a new position in TriSalus Life Sciences during the 4th quarter valued at about $67,000. Northern Trust Corp increased its position in TriSalus Life Sciences by 22.7% during the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after purchasing an additional 5,936 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of TriSalus Life Sciences by 120,471.6% in the fourth quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock valued at $894,000 after buying an additional 178,298 shares during the last quarter. Hedge funds and other institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Price Performance

Shares of NASDAQ:TLSI traded down $0.02 during trading hours on Friday, hitting $5.71. The company's stock had a trading volume of 3,739 shares, compared to its average volume of 44,252. The company has a market capitalization of $173.96 million, a price-to-earnings ratio of -2.29 and a beta of 0.49. The firm's fifty day moving average price is $5.51 and its 200 day moving average price is $4.87. TriSalus Life Sciences has a 52 week low of $3.50 and a 52 week high of $10.24.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.35) EPS for the quarter, meeting analysts' consensus estimates of ($0.35). The business had revenue of $8.26 million during the quarter, compared to analysts' expectations of $8.12 million. On average, equities research analysts predict that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.